Cleerly is bringing machine intelligence technology to heart disease solutions and investors are pouring in funds. New York-based Cleerly, the producer of FDA-approved, non-invasive heart disease solutions, recently announced that it has raised a $223 million Series C round.
The raise was led by funds and accounts advised by T. Rowe Price Associates, T. Rowe Price Investment Management and Fidelity Management and Research Company with participation from other healthcare and technology investors.
The $223 million Series C brings Cleerly’s total capital raised to date to $279 million, including a $43 million Series B.
The company’s technology is able to measure plaque build-up in the heart’s arteries and then provides a heart disease diagnosis that helps patients and physicians determine next steps. This can help improve financial and clinical results, according to Cleerly.
After its Series B raise last year, Cleerly CEO and founder Dr. James Min told Built In that the company expanded its executive team with the appointment of a chief operating officer, chief technology officer and chief revenue officer. In addition, Cleerly added three new members to its board of directors. Min said these appointments contributed to the company’s ability to raise a Series C round.
“We are grateful for this round of financing that will further enable our work and believe it provides a resounding vote of confidence in our vision for the future of cardiovascular care,” Min said in a statement. “The status quo for heart health simply isn’t good enough — for patients, providers or payors — and our proven approach to examining for early signs of heart disease through the build-up of arterial plaque promises to deliver the change we need right now.”
With its fresh funds, Cleerly plans to expand its reach to more physicians and patients. Additional funds will go toward hiring, specifically for the company’s commercial, technology, market access and reimbursement teams.
